

## Supplementary Materials

### Tables

**Table S1**

Formulation of Compound Emulsifier

HLB <sub>mix</sub>	Tween80 (%)	Span80 (%)
4.3	0	100
9	44	56
10.5	58	42
12	72	28
13.5	86	14
16	100	0

**Table S2**

Variables and their levels in the Box-Behnken design.

	Levels		
	-1	0	1
Independent variables			
A=ratio of oil (%)	4	10	16
B=ratio of Smix (%)	20	25	30
C=stirring time (h)	0.5	1.0	1.5
Dependent variables	Constraints		
Y1=mean particle size (MPS, nm)	Minimize		
Y2= polymer dispersity index (PDI)	Minimize		
Y3=zeta potential (ZP, mV)	Minimize		

**Table S3**

MS detection conditions for the five components of VOC

component	[M+H] <sup>+</sup> (m/z)	DP(V)	CE(eV)	Retention time (min)
NBP	191.3→116.9	76	29	4.14
SA	193.1→136.8	76	17	3.96
ZL	191.1→145.0	72	20	5.05
BP	189.3→128.0	76	35	5.13
NOL	195.0→149.0	79	14	4.78
DL (IS)	231.0→185.1	89	18	5.49

**Table S4**

Effects of surfactants on nanoemulsions

Surfactant Type	traits	Size/nm
Span 80	cloudy, layered	-
Tween 80	cloudy	Yellow-white lotion
RH40	clear, transparent	23.11±0.12

Compound emulsifier 1 (HLB=9)	cloudy	Yellow-white lotion
Compound emulsifier 2 (HLB=10.5)	cloudy	Yellow-white lotion
Compound emulsifier 3 (HLB=12)	cloudy	Yellow-white lotion
Compound emulsifier 4 (HLB=13.5)	cloudy, layered	Yellow-white lotion

**Table S5**

Summary of results of regression analysis for the considered responses Y1-Y3.

Factors	MPS(Y1)		PDI(Y2)		ZP(Y3)	
	Coefficient	P-value	Coefficient	P-value	Coefficient	P-value
Model	8	0.006*	1.89	0.2073	6.15	0.0129*
A	26.8	0.0013*	4.82	0.0641	1.45	0.2681
B	0.08	0.7857	1.85	0.2154	12.92	0.0088*
C	8.09	0.0249*	1.12	0.3259	1.04	0.3427
AB	6.12	0.0426*	0.26	0.6251	17.71	0.004*
AC	3.2	0.1166	0.006	0.9395	8.77	0.0211*
BC	2.95	0.1297	0.15	0.706	7.55	0.0286*
A <sup>2</sup>	0.29	0.6078	2.1	0.1909	2.43	0.1627
B <sup>2</sup>	8.4	0.0231*	0.11	0.7535	2.6	0.1509
C <sup>2</sup>	14.27	0.0069*	6.89	0.0341*	1.11	0.3268
Lack of Fit	6.29	0.0539	4.59	0.0875	5.27	0.0711
R <sup>2</sup>	0.9113		0.7081		0.8877	

Note: \*significant value, with a 95% confidence interval. R<sup>2</sup> is the correlation coefficient.

**Table S6**

Predicted versus observed values of optimized VOC-NE.

Dependent variables	Predicted	Observed	Prediction error (%)
Y1=mean particle size (nm)	21.38	21.02±0.17	1.71
Y2=polymer dispersity index	0.14	0.15±0.02	6.67
Y3=zeta potential (mV)	-20.73	-20.40±1.47	1.60

**Table S7**

Fitting results of in vitro release model of VOC-NE-ISG (n=3, X±SD)

Model	Zero	First	Higuchi	Ritger-peppas
SA	Y=7.37+3.61x	lnY=94.89+0.08x	Y = 18.31√x - 7.58	Y=10.77x <sup>0.66</sup>
	R <sup>2</sup> =0.9356	R <sup>2</sup> =0.9800	R <sup>2</sup> =0.9852	R <sup>2</sup> =0.9973
NOL	Y=8.20+3.12x	lnY=90.57+0.07x	Y = 15.61√x - 4.23	Y=10.07x <sup>0.64</sup>
	R <sup>2</sup> =0.9607	R <sup>2</sup> =0.9746	R <sup>2</sup> =0.9709	R <sup>2</sup> =0.9856
NBP	Y=8.99+3.17x	lnY=93.34+0.07x	Y = 15.78√x - 3.51	Y=10.66x <sup>0.63</sup>

	$R^2=0.9622$	$R^2=0.9627$	$R^2=0.9659$	$R^2=0.9808$
ZL	$Y=4.50+3.11x$	$\ln Y=96.72+0.05x$	$Y = 15.47\sqrt{x} - 7.73$	$Y=7.17x^{0.74}$
	$R^2=0.9531$	$R^2=0.9765$	$R^2=0.9542$	$R^2=0.9855$
BP	$Y=4.98+280x$	$\ln Y=91.90+0.05x$	$Y = 13.87\sqrt{x} - 5.92$	$Y=6.70x^{0.72}$
	$R^2=0.9551$	$R^2=0.9716$	$R^2=0.9718$	$R^2=0.9846$


**Table S8**

Pharmacodynamic evaluation of VOC-NE-ISG. (n=10,  $\bar{X}\pm SD$ )


group	n	Neurological score after MCAO modeling	Post-dose neurological score	infarct size/%
Sham	10	0.00±0.00	0.00±0.00	0.00±0.00
MCAO	10	2.17±0.72	2.50±0.50	41.36±4.83
MCAO+NBP	10	2.70±0.67	1.20±0.60*	23.02±2.30**
MCAO+NE	10	2.33±0.78	1.60±0.92	31.65±2.60*
MCAO+NE-ISG	10	2.38±0.65	1.30±0.78*	25.14±4.26**

Note: \*P<0.05, \*\*P<0.01 VS model group.


## Figures




**Figure S1.** Gel strength measuring device; (A) weights; (B) device; (C) mess cylinder; (D) poloxamer gel




**Figure S2.** Bioadhesive force-measuring device, (A)modified balance; (B)weights; (C)glass vial; (D)poloxamer gel; (E)nasal mucosa; (F)height-adjustable pan.




**Figure S3.** Solubility of VOC in different surfactants and cosurfactants.



**Figure S4.** Pseudo ternary phase diagram.




**Figure S5.** 3D surface and interaction plots showing the effects of the independent variables on particle size of VOC-NE.




**Figure S6.** 3D surface and interaction plots showing the effects of the independent variables on zeta potential of VOC-NE.




**Figure S7.** The volatile oil of Chaxiong nanoemulsion




**Figure S8.** Identification results of VOC-NE by staining (left: Sudan red III; right: methylene blue)



**Figure S9.** The particle size distribution and potential distribution of VOC-NE.




**Figure S10.** Effect of P407 concentration on the gelling temperature of in situ gels




**Figure S11.** The effect of P188 concentration on gelation temperature






**Figure S12.** The effect of P407 and P188 concentration on gelation temperature of VOC-NE-ISG




**Figure S13.** Liquid-solid transition state of VOC-NE-ISG (left: liquid state; right: gel state)



**Figure S14.** Rheological evaluation of VOC-NE-ISG

A. Linear viscoelastic interval diagram of VOC-NE-ISG B. Frequency scanning curves of VOC-NE-ISG C.  $\tau$  change curves of CPTA-NE-ISG as a function of  $\gamma'$  at different temperature. D.  $\eta$  change curves of CPTA-NE-ISG as a function of  $\gamma'$  at different temperature.



**Figure S15.** In vitro release curve of VOC-NE-ISG



**Figure S16.** The MCAO model rats